Depression is a complex disorder involving disturbances in neurotransmitter regulation, emotional processing, autonomic nervous system function, and neurobiological signaling pathways. Although procaine is best known as a local anesthetic, several decades of pharmacological and clinical research have suggested that its effects extend beyond anesthesia and may influence multiple systems involved in mood regulation.
Three independent lines of investigation have explored procaine's relationship to depression. These include clinical studies of Gerovital H3 (a procaine derivative) in depressed patients, biochemical investigations of procaine metabolism and neurotransmitter regulation, and neuroimaging studies examining procaine's effects on limbic and cholinergic brain pathways.
One of the most direct evaluations of procaine-related therapy in depression was a four-week double-blind, placebo-controlled study involving 63 outpatients aged 45 to 83 years with mild to moderate depressive disorders.
Participants received either Gerovital H3 (GH3), a Romanian formulation of procaine hydrochloride, or placebo. Depression severity was measured using the Clinical Global Impression Scale (CGI), Hamilton Rating Scale for Depression (HRD), and Zung Self-Rating Depression Scale (SDS).
Patients treated with Gerovital H3 demonstrated statistically significant improvements across all three depression scales. Although some placebo response was observed, improvements were consistently greater in the treatment group. The therapy was generally well tolerated, with only minor adverse effects reported, including occasional sweating, dizziness, tremor, palpitations, and muscle discomfort.
Based on these findings, the investigators concluded that Gerovital H3 was significantly more effective than placebo in treating mild to moderate depressive disorders and appeared to be safe and well tolerated.
Research examining procaine metabolism suggests that its effects may involve multiple neurotransmitter systems known to participate in mood regulation.
Following administration, procaine is metabolized into compounds including diethylaminoethanol (DEAE) and para-aminobenzoic acid (PABA). The interaction of these metabolites appears to influence several biochemical pathways associated with emotional regulation and central nervous system function.
According to the authors, procaine may help restore balance between cholinergic, catecholaminergic, and indolaminergic neurotransmitter systems. These neurotransmitter networks are involved in mood, cognition, motivation, reward processing, and emotional stability.
The investigators proposed that this broad neurochemical influence may help explain observations of beneficial effects in both depressive and manic states.
A recurring finding across the depression literature reviewed by the authors is procaine's interaction with monoamine oxidase (MAO).
Gerovital H3 was described as a reversible, competitive inhibitor of MAO and was reported to inhibit MAO activity more effectively than procaine alone. Because MAO enzymes are responsible for the breakdown of neurotransmitters involved in mood regulation, inhibition of these enzymes may contribute to improved neurotransmitter availability.
The authors further discussed theories suggesting that increased MAO activity may occur with aging and may contribute to depressive symptoms. Consequently, modulation of MAO activity was proposed as one mechanism through which procaine-related therapies may influence depression.
Beyond classical neurotransmitter effects, procaine has been proposed to interact with several metabolic and regulatory pathways.
The reviewed research described:
The authors suggested that these mechanisms may contribute to procaine's observed effects on mood regulation and may help explain why its actions extend beyond those expected from a local anesthetic.
Neuroimaging studies provide additional insight into how procaine may affect brain regions involved in emotion.
Positron emission tomography (PET) studies demonstrated that intravenous procaine binds strongly to muscarinic cholinergic receptors throughout the brain. At higher doses, procaine blocked approximately 90 percent of muscarinic receptor binding, indicating substantial interaction with the cholinergic system.
Although receptor binding occurred broadly, the greatest increases in cerebral activity were observed within limbic and paralimbic structures, including:
These regions play important roles in emotional processing, memory, motivation, autonomic regulation, and behavioral responses.
Investigators proposed that activation of muscarinic cholinergic pathways within these regions may contribute to the emotional and sensory effects observed after intravenous procaine administration.
The limbic imaging findings support a broader hypothesis that cholinergic signaling participates in mood regulation.
The authors reviewed evidence that cholinergic neurotransmission influences emotional arousal, depression, reward pathways, and stress responses. Because procaine demonstrated strong binding to muscarinic cholinergic receptors and increased activity in brain regions involved in emotional processing, they proposed that cholinergic mechanisms may be one pathway through which procaine influences mood.
These observations were considered particularly relevant because the same limbic structures activated by procaine have been implicated in mood disorders and emotional regulation.
The limbic imaging findings support a broader hypothesis that cholinergic signaling participates in mood regulation.
The authors reviewed evidence that cholinergic neurotransmission influences emotional arousal, depression, reward pathways, and stress responses. Because procaine demonstrated strong binding to muscarinic cholinergic receptors and increased activity in brain regions involved in emotional processing, they proposed that cholinergic mechanisms may be one pathway through which procaine influences mood.
These observations were considered particularly relevant because the same limbic structures activated by procaine have been implicated in mood disorders and emotional regulation.
Depression frequently occurs in older adults and is commonly associated with neurodegenerative disorders such as Alzheimer's disease.
The authors noted that procaine's effects on neurotransmitter balance, monoamine oxidase activity, methylation pathways, gene expression, and limbic system activation provide several theoretical mechanisms through which it may influence mood disorders in aging populations.
Based on these observations, they argued that procaine should not be viewed solely as a local anesthetic but rather as a compound with broader neurobiological actions deserving further investigation in geriatric and neuropsychiatric medicine.
The available evidence suggests that procaine may influence depression through multiple interconnected mechanisms. Clinical studies demonstrated improvement in mild to moderate depressive symptoms with Gerovital H3 treatment. Pharmacological investigations identified effects on monoamine oxidase activity, neurotransmitter regulation, methylation pathways, and gene expression. Neuroimaging studies further demonstrated strong interactions with muscarinic cholinergic receptors and increased activity within limbic brain regions involved in emotion and mood regulation.
Taken together, these findings suggest that procaine possesses neurochemical and neurophysiological actions extending beyond local anesthesia and may influence several biological systems involved in depressive disorders. The authors of these studies advocate for continued investigation into its potential role in the prevention and treatment of depression, particularly in aging populations and individuals with neurodegenerative disease.
Copyright © 2026 NY 360 Wellness Medicine - All Rights Reserved.
NY 360 Wellness Medicine is a functional medicine and longevity clinic in New York specializing in hormone therapy, fatigue, weight management, gut health, and preventive Medicine 3.0 care. We provide personalized, physician-led treatment plans using advanced diagnostics and integrative therapies to help people achieve long-term health and vitality.
Become a part of the elite group of members who will be eligible for 15% off all membership tiers if you sign up before June 15th.
Use code: Founder